Unknown

Dataset Information

0

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.


ABSTRACT: Triple-negative breast cancer (TNBC) is a major cause of death among breast cancer patients that results from intrinsic and acquired resistance to systemic chemotherapies. To identify novel targets for effective treatment of TNBC through combination strategies with MEK inhibitor (AS703026), we used a novel method of combining high-throughput two- and three-dimensional (2D and 3D) RNAi screening. TNBC cells were transfected with a kinome siRNA library comprising siRNA targeting 790 kinases under both 2D and 3D culture conditions with or without AS703026. Molecule activity predictor analysis revealed the PI3K pathway as the major target pathway in our RNAi combination studies in TNBC. We found that PI3K inhibitor SAR245409 (also called XL765) combined with AS703026 synergistically inhibited proliferation compared with either drug alone (P < 0.001). Reduced in vitro colony formation (P < 0.001) and migration and invasion ability were also observed with the combination treatment (P<0.01). Our data suggest that SAR245409 combined with AS703026 may be effective in patients with TNBC. We conclude that a novel powerful high-throughput RNAi assays were able to identify anti-cancer drugs as single or combinational agents. Integrated and multi-system RNAi screening methods can complement difference between in vitro and in vivo culture conditions, and enriches targets that are close to the in vivo condition.

SUBMITTER: Lee J 

PROVIDER: S-EPMC4643087 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4588757 | BioStudies
2016-01-01 | S-EPMC4873419 | BioStudies
1000-01-01 | S-EPMC3064692 | BioStudies
1000-01-01 | S-EPMC6044050 | BioStudies
2019-01-01 | S-EPMC6597235 | BioStudies
2010-01-01 | S-EPMC2917036 | BioStudies
2016-01-01 | S-EPMC5045418 | BioStudies
2012-01-01 | S-EPMC3416967 | BioStudies
2019-01-01 | S-EPMC6642106 | BioStudies
2014-01-01 | S-EPMC4184972 | BioStudies